title: Scaling up prevention of mother-to-child HIV transmission programs in sub-Saharan African countries: a multilevel assessment of site-, program- and country-level determinants of performance.
abstract: BACKGROUND
  Uptake of prevention of mother-to-child HIV transmission (PMTCT) programs remains challenging in sub-Saharan Africa because of multiple barriers operating at the individual or health facility levels. Less is known regarding the influence of program-level and contextual determinants. In this study, we explored the multilevel factors associated with coverage in single-dose nevirapine PMTCT programs.
  
  
  METHODS
  We analyzed aggregate routine data collected within the framework of the Viramune(®) Donation Programme (VDP) from 269 sites in 20 PMTCT programs and 15 sub-Saharan countries from 2002 to 2005. Site performance was measured using a nevirapine coverage ratio (NCR), defined as the reported number of women receiving nevirapine divided by the number of women who should have received nevirapine (observed HIV prevalence x number of women in antenatal care [ANC]). Data on program-level determinants were drawn from the initial application forms, and country-level determinants from the Demographic and Health Surveys (DHS) and the World Bank (World Development Indicators). Multilevel linear mixed models were used to identify independent factors associated with NCR at the site-, program- and country-level.
  
  
  RESULTS
  Of 283,410 pregnant women attending ANC in the included sites, 174,312 women (61.5%) underwent HIV testing after receiving pre-test counselling, of whom 26,700 tested HIV positive (15.3%), and 22,591 were dispensed NVP (84.6%). Site performance was highly heterogeneous between and within programs. Mean NCR by site was 43.8% (interquartile range: 19.1-63.9). Multilevel analysis identified higher HIV prevalence (Beta coefficient: 25.1, 95% confidence interval [CI] 18.7 to 31.6), higher proportion of persons with knowledge of PMTCT (8.3; CI 0.5 to 16.0), higher health expenditure as a proportion of Gross Domestic Product (3.9 per %; CI 2.0 to 5.8) and lower percentage of rural population (-0.7 per %; CI -1.0 to -0.5) as significant country-level predictors of higher NCR at the p<0.05 level. A medium ANC monthly activity (30-100/month) was the only site-level predictor found (-7.6; CI -15.1 to -0.1).
  
  
  CONCLUSIONS
  Heterogeneity of nevirapine coverage between sites and programs was high. Multilevel analysis identified several significant contextual determinants, which may warrant additional research to further define important multi-level and potentially modifiable determinants of performance of PMTCT programs.
authors.affiliation: Biostatistics and Epidemiology Unit, Hôtel Dieu, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Sorbonne Paris Cité, Paris, France. Etienne.Audureau@yahoo.fr
authors.forename: Etienne
authors.initials: E
authors.lastname: Audureau
authors.forename: James G
authors.initials: JG
authors.lastname: Kahn
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Besson
authors.forename: Joseph
authors.initials: J
authors.lastname: Saba
authors.forename: Joël
authors.initials: J
authors.lastname: Ladner
mesh_terms: D017954:Africa South of the Sahara; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D055361:Multilevel Analysis; D019829:Nevirapine / Q000627:therapeutic use*; D011247:Pregnancy; D011295:Prenatal Care / Q000458:organization & administration*; D015397:Program Evaluation; D012307:Risk Factors; D012959:Socioeconomic Factors
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine
references.citation: J Obstet Gynaecol. 2004 Apr;24(3):266-9
references.pmid: 15203622
references.citation: JAMA. 2000 Mar 1;283(9):1175-82
references.pmid: 10703780
references.citation: Soc Sci Med. 2009 Sep;69(6):838-45
references.pmid: 19576671
references.citation: BMJ. 2004 Nov 13;329(7475):1147-50
references.pmid: 15539670
references.citation: Lancet. 2002 Jun 15;359(9323):2097-104
references.pmid: 12086778
references.citation: AIDS. 2002 May 3;16(7):953-9
references.pmid: 11953461
references.citation: J Health Popul Nutr. 2005 Mar;23(1):58-65
references.pmid: 15884753
references.citation: S Afr Med J. 2009 Mar;99(3):174-9
references.pmid: 19563095
references.citation: BMC Public Health. 2012 Jan 11;12:26
references.pmid: 22236097
references.citation: AIDS Res Ther. 2005 Oct 28;2:10
references.pmid: 16255776
references.citation: AIDS Care. 2011 Jun;23(6):741-7
references.pmid: 21293987
references.citation: AIDS. 2003 Jun 13;17(9):1377-82
references.pmid: 12799559
references.citation: PLoS One. 2012;7(1):e29823
references.pmid: 22276130
references.citation: J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):114-8
references.pmid: 16340483
references.citation: Trop Med Int Health. 2004 Jul;9(7):774-83
references.pmid: 15228487
references.citation: HIV Med. 2011 Aug;12(7):422-7
references.pmid: 21251184
references.citation: AIDS. 2010 Jan 28;24(3):447-55
references.pmid: 19926959
references.citation: West Indian Med J. 2004 Oct;53(5):293-6
references.pmid: 15675493
references.citation: AIDS. 2011 Jul 31;25(12):1523-33
references.pmid: 21750418
references.citation: Am J Obstet Gynecol. 2007 Sep;197(3 Suppl):S107-12
references.pmid: 17825641
references.citation: BMC Public Health. 2010 Apr 28;10:218
references.pmid: 20426830
references.citation: JAMA. 2010 Jul 21;304(3):293-302
references.pmid: 20639563
references.citation: AIDS Patient Care STDS. 2007 Apr;21(4):252-60
references.pmid: 17461720
references.citation: J Acquir Immune Defic Syndr. 2011 Jul 1;57 Suppl 1:S3-8
references.pmid: 21857283
references.citation: Lancet. 1999 Sep 4;354(9181):795-802
references.pmid: 10485720
references.citation: Lancet. 1995 Apr 15;345(8955):969-70
references.pmid: 7619122
references.citation: AIDS. 2003 May 23;17(8):1239-42
references.pmid: 12819526
references.citation: Am J Public Health. 2009 Apr;99(4):631-7
references.pmid: 18703458
references.citation: Trop Med Int Health. 2005 Dec;10(12):1242-50
references.pmid: 16359404
references.citation: BMC Public Health. 2009 Aug 27;9:314
references.pmid: 19712454
references.citation: Afr Health Sci. 2005 Sep;5(3):213-8
references.pmid: 16245991
references.citation: AIDS. 2007 Nov 30;21(18):2529-32
references.pmid: 18025890
references.citation: J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):344-9
references.pmid: 16249710
references.citation: Curr Opin Pediatr. 2009 Feb;21(1):94-101
references.pmid: 19242245
references.citation: J Acquir Immune Defic Syndr. 2010 Nov;55(3):287-9
references.pmid: 20714271
references.citation: AIDS Care. 2012;24(2):259-65
references.pmid: 21780955
references.citation: Acta Paediatr. 2011 Sep;100(9):1253-7
references.pmid: 21366691
references.citation: AIDS. 2008 May 11;22(8):973-81
references.pmid: 18453857